For the second quarter of the fiscal year ending March 2027, revenue was 266,490 million yen (up 17.3% year-over-year), core operating profit was 421 hundred million yen, and interim profit attributable to owners of the parent was 38,238 million yen. Full-year forecasts were revised to revenue of 565,000 million yen, core operating profit of 105,000 million yen, and profit for the year of 94,000 million yen. The dividend forecast was also updated. The performance was supported by a weaker yen and expansion in the U.S. market. Segments were consolidated into a single Pharmaceuticals segment. An earnings presentation is scheduled.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4506","jir_company_name":"Sumitomo Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4506-20261030-01.pdf","jir_short_summary":"For the second quarter of the fiscal year ending March 2027, revenue was 266,490 million yen (up 17.3% year-over-year), core operating profit was 421 hundred million yen, and interim profit attributable to owners of the parent was 38,238 million yen. Full-year forecasts were revised to revenue of 565,000 million yen, core operating profit of 105,000 million yen, and profit for the year of 94,000 million yen. The dividend forecast was also updated. The performance was supported by a weaker yen and expansion in the U.S. market. Segments were consolidated into a single Pharmaceuticals segment. An earnings presentation is scheduled.","jir_summary":"### Overview of Results\nIn this interim report, revenue increased significantly year-over-year while core operating profit and operating profit declined substantially. The revenue growth reflected expansion in the U.S. market, the impact of a weaker yen, and structural effects from segment changes. The Financial Summary revises the full-year guidance to revenue of 565,000 million yen, core operating profit of 105,000 million yen, and profit for the year attributable to owners of the parent of 94,000 million yen. An earnings presentation will be held.\n\n### Impact for Shareholders and Outlook\nThe revision to the full-year guidance has prompted a reassessment of expectations for future profit growth. Integration into a single Pharmaceuticals segment is expected to improve operational transparency. Refer to the announced notice for details on the revised dividend forecast. Exchange rate assumptions and progress in the U.S. market will be key drivers of future performance.","jir_financial_highlights":"Revenue: 266,490 (Year-over-Year +17.3%)\nCore Operating Profit: 421 (Year-over-Year -56.2%)\nOperating Profit: 42,276 (Year-over-Year -56.0%)\nInterim Profit: 38,238 (Year-over-Year -61.3%)\nInterim Profit Attributable to Owners of the Parent: 38,238 (Year-over-Year -61.3%)\nFull-Year Revenue Guidance: 565,000 (vs. Previous Guidance +25,000)\nEarnings per Share: 211.07 (vs. Previous Guidance +? (see notes))","jir_category":"","jir_hashtags":"#SumitomoPharma, #Earnings, #IFRS, #Pharmaceuticals","jir_key_figures":"Revenue: 266,490 million yen (Year-over-Year +17.3%)\nCore Operating Profit: 421 million yen\nInterim Profit: 38,238 million yen\nFull-Year Revenue Guidance: 565,000 million yen","jir_meta_title":"Sumitomo Pharma Co., Ltd. \u2014 Q2 FY2027 Financial Summary | Revenue 266,490 million yen, Revised Full-Year Guidance","jir_meta_description":"Sumitomo Pharma Co., Ltd. Q2 FY2027 financial summary. Revenue: 266,490 million yen; core operating profit: 421 hundred million yen. Full-year revenue guidance revised to 565,000 million yen. Driven by FX impact and U.S. market expansion.","jir_og_title":"Sumitomo Pharma Co., Ltd. Q2 Financial Results | Revenue 266,490 million yen","jir_og_description":"Interim results for Sumitomo Pharma Co., Ltd.: revenue increased year-over-year and full-year guidance was revised, supported by U.S. market expansion and foreign exchange effects.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025\/4-9\\\",\\\"2026\/4-9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[227122,266490]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Profit Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025\/4-9\\\",\\\"2026\/4-9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Profit\\\",\\\"data\\\":[962,42276]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Margin Analysis\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Revenue\\\",\\\"Core Operating Profit\\\",\\\"Operating Profit\\\"],\\\"datasets\\\":[{\\\"data\\\":[2664.9,421,422.76]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"U.S.\\\",\\\"Japan\\\",\\\"Other\\\"],\\\"datasets\\\":[{\\\"data\\\":[1978,446,241]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Guidance vs. Results Comparison\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Revenue\\\",\\\"Core Operating Profit\\\",\\\"Profit Attributable to Owners of the Parent\\\"],\\\"datasets\\\":[{\\\"data\\\":[565000,105000,94000]},{\\\"data\\\":[540000,91000,77800]}]},\\\"options\\\":{}}\"}]","ir_related_company":7612,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-138888","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n